|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01548 GENSCRIPT BIO
Nominal 
12.500 +0.060 (+0.482%) | 2024/12 - Final USD(K$) | %Chg (Compare to Final) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | 2020/12 USD(K$) | |
| Turnover | 594,486 | -29.188% | 839,529 | 625,698 | 490,096 | 390,846 |
| Cost of Sales | (322,361) | -25.028% | (429,976) | (321,615) | (207,578) | (134,953) |
| Gross Profit | 272,125 | -33.556% | 409,553 | 304,083 | 282,518 | 255,893 |
| 2024/12 - Final USD(K$) | %Chg (Compare to Final) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | 2020/12 USD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (175,650) | -- | 27,020 | 6,140 | (140,864) | (79,977) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (39,072) | 2723.121% | (1,384) | (27) | 0 | (599) | |
| Profit / (Loss) before Taxation | (170,797) | -51.337% | (350,979) | (431,690) | (517,363) | (281,900) | |
| Taxation | (2,977) | -28.127% | (4,142) | 3,719 | (964) | 477 | |
| Profit / (Loss) from Discontinued Operations | 3,029,061 | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 106,590 | -58.948% | 259,644 | 201,120 | 159,615 | 76,478 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,961,877 | -- | (95,477) | (226,851) | (358,712) | (204,945) | |
| 2024/12 - Final USD(K$) | %Chg (Compare to Final) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | 2020/12 USD(K$) | |
| Net Finance Costs / (Income) | 8,032 | -70.803% | 27,510 | 13,269 | (407) | 1,134 |
| Depreciation & Amortisation | 61,538 | -16.892% | 74,046 | 64,248 | 47,779 | 32,895 |
| Directors' Emoluments | -- | -- | 2,294 | 3,042 | 2,860 | 1,865 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified (Modified Report) | Unqualified (Modified Report) |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 139.630 | -- | -4.530 | -10.820 | -17.670 | -10.780 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.036 | -- | (0.136) | (0.057) | (0.067) | (0.079) |
| NBV per share ($) | 2.016 | -- | 0.655 | 0.478 | 0.498 | 0.462 |
| Remarks: | Real time quote last updated: 14/03/2025 09:46 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | USD 2,961,877,000 |
| %Change | -- |
| EPS / (LPS) | USD 1.396 |
| NBV Per Share ($) | USD 2.016 |